Intent to Sole Source - Medical/Scientific Instruments for the Department of Transfusion Medicine, NIH Clinical Center
National Institutes of Health · NATIONAL INSTITUTES OF HEALTH
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation NOI-OLAO-CC-27-000121 in this department, oldest first.
- Oct 8, 2026Special NoticeOpen
- Oct 8, 2026 · this noticeSpecial Notice
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Answer the notice: this is when the requirement can still be shaped.
- Contact the contracting officer named on the notice.
- Check who won similar work; they are the likely bidders.
What the notice says
This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with the following vendor: Fisher Scientific. Acquisition Description: The NIH Clinical Center, Department of Transfusion Medicine (DTM), Infectious Diseases Section requires acquisition of a 1) Real-Time PCR System, 2) an Automated Nucleic Acid Extractor and 3) a microvolume spectrophotometer to support clinical research and the development, optimization, and validation of diagnostic assays for hepatitis viruse… (show all)
s and other transfusion-transmitted pathogens. The required system must support generation of high-quality quantification data from clinical specimens, including viral RNA/DNA and host-derived nucleic acids. The instrument must enable applications such as targeted genome amplification, work with a wider dynamic detection range, support the library prep for viral genome sequencing, and assay development workflows necessary for evaluating test performance and refining diagnostic methods prior to implementation in a clinical testing environment. The system must meet the following functional and operational requirements: High data accuracy and reproducibility to ensure reliable detection of viral variants and evaluation of assay performance; Low- to moderate-throughput capability appropriate for assay development, pilot studies, and validation activities involving smaller sample sets; Rapid turnaround times to support iterative testing and optimization of clinical assays; Flexible run configurations that allow efficient processing of varying sample volumes without excess capacity; Cost-efficient operation, including the ability to minimize per-run and per-sample costs for pathogen detection; Integrated and streamlined workflows, including nucleic acid extraction, amplification, quantification and data analysis within a platform from the same vendor to reduce complexity and variability; Ease of use and standardized operation, supporting reproducibility and implementation in a clinical laboratory environment; Compatibility with established nucleic acid preparation and amplification methods and existing laboratory workflows. The flexibility to be using the systems in a CLIA certified environment. The statutory authority for this sole source requirement is 41 U.S.C. 253(c) (1) as implemented by FAR 6.302-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-OLAO-CC-27-000121) by 12:00 PM eastern standard time on 10/23/2026 to: valerie.gregorio@nih.gov. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
Who won similar work
27 award notices on SAM.gov in the last 24 months. Matched by: Same agency (National Institutes of Health), same product/service code (PSC) 6640.
Single-winner award sizes (27): middle half $41K to $199K, median $56K; range $21K to $1.8M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| BRUKER BIOSPIN CORP · $BRKR · $3.0B | 3 | $1.7M | Jul 30, 2026 |
| GOVERNMENT SCIENTIFIC SOURCE INC | 3 | $318K | Jan 9, 2026 |
| FEI COMPANY | 1 | $1.8M | Sep 22, 2025 |
| TECNIPLAST USA, INC. | 1 | $245K | Sep 8, 2025 |
| BRUKER NANO, INC · $BRKR · $3.0B | 1 | $230K | Aug 14, 2026 |
| Sony Biotechnology Inc. | 1 | $227K | Aug 17, 2026 |
| NEWPORT CORP | 1 | $212K | Jul 8, 2026 |
| AMUZA INC. | 1 | $115K | Jul 10, 2026 |
| IQVIA GOVERNMENT SOLUTIONS INC | 1 | $74K | Jan 23, 2026 |
| IRADIMED CORPORATION | 1 | $71K | Jun 30, 2026 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.
- $BRKR reported $3.0B revenue in FY2025. The median single-winner award in these 27 past awards, $56K, is under 0.1% of that. 10-K
One award's total value against one year of revenue; many awards are paid over several years.
- Oct 9, 2026Revvity Health Sciences, Inc.$21KAutomated Cell Counter and AnalyzerNo listed company matched (Materiality N/A)
- Sep 25, 2026NIKON INSTRUMENTS INC$40K66--Warming Box/Enclosure for Nikon Eclipse Ti-2 AX coNo listed company matched (Materiality N/A)
- Aug 17, 2026Sony Biotechnology Inc.$227K66--NIMH: Purchase order for One (1) Microfluidic BaseNo listed company matched (Materiality N/A)
- Aug 14, 2026BRUKER NANO, INC$230K66--NIMH: Purchase order for One (1) Miniaturized HeadMateriality: <0.01% of $BRKR revenue (Low) SEC
- Aug 7, 2026BITTIUM USA INC.$48K66--NIMH: Non Competitive Combined Synopsis for FarosNo listed company matched (Materiality N/A)
- Jul 30, 2026BRUKER BIOSPIN CORP$143K66--NIMH: One (1) 2000W MRI RF Power Amplifier and assMateriality: <0.01% of $BRKR revenue (Low) SEC
- Jul 10, 2026AMUZA INC.$115K66--NIMH: Purchase order for four (4) wireless fiber pNo listed company matched (Materiality N/A)
- Jul 10, 2026BECKMAN COULTER, INC$31K66--Purchase Order for two (2) Hematology AnalysersNo listed company matched (Materiality N/A)
- Jul 8, 2026NATIONWIDE POWER SOLUTIONS INC$37K66--NIMH: Purchase Ornder for the replacement parts anNo listed company matched (Materiality N/A)
- Jul 8, 2026NEWPORT CORP$212K66--RFQ for One (1) Tunable Laser Multi-Photon MicroscNo listed company matched (Materiality N/A)
Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.
Competitive landscape
For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 0 of these past winners lobbied Natl Institutes of Health (NIH) since 2024 (0 filings)
- 0 of their lobbyists list a past Natl Institutes of Health (NIH) job
- No corporate PAC money from them to the overseeing committees since 2024
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 0 bills named on the past winners' lobbying filings
- 0 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 1 of the past winners are listed companies
- 0 insider buys and 0 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.